Onward Medical NV (ONWRY / ONWD) makes ARC Therapy — targeted electrical stimulation of the spinal cord to restore hand function and movement after spinal cord injury. It is the only FDA-cleared device for SCI hand strength in the US. The stock is near its 52-week low ($3.06–$7.13 range) following sector rotation away from non-AI medtech, and the Q1 2026 earnings call surfaced a specific, near-term revenue signal the market has not priced.

What the Filing Says

VA dry powder. Approximately one-third of Q1 2026 units (≈23 of 70 supplied) were Veterans Affairs evaluation units — not yet recognized as product revenue. VA procurement follows a fixed sequence: two-month evaluation period plus ≈30-day PO generation. CEO Marver on the Q1 call: "We have a lot of demand that we enjoyed in Q1, some of it in sales, the EUR 1.3 million. A lot of it is dry powder that you'll see result in sales next quarter." At $29K/unit, the pending pipeline represents approximately EUR 600K of identifiable Q2 revenue not in Q1 actuals.

First structural inflection. Q1 was the first quarter home units exceeded clinic units. Marver: "For the first time, we sold more personal or home units than clinic units. That's certainly a trend we would expect to continue going forward." The US clinic market has ≈400 specialized SCI rehab centers; the company is at 100+, roughly 25% penetrated. The home market has no comparable ceiling.

Cash extended to Q1 2028. An April 2026 EUR 40M raise anchored by EQT Life Sciences (EUR 25M) brought the cash balance to EUR 89.8M. Runway extended from approximately 7-8 months to two years. CEO: "Very strong. That's as much runway as we've ever had since I joined in 2020." Top two shareholders are now EQT Life Sciences and Ottobock.

Empower BP pivotal progressing. First patient enrolled and implanted Q1 2026 at Craig Hospital, Denver. 12 US sites active (up from 10 at Q4). Interim analysis target: early 2027 (33 patients at 3-month follow-up). PMA target: H2 2028.

Grant income ceiling. Q1 grant income of EUR 0.7M should not be annualized. CEO explicitly warned: "Do not straight line that EUR 700,000... we do not expect grant income to be EUR 2.8–3 million this year. Significantly less than that."

What the Market Thinks

Down 29% year-over-year, near its 52-week low. No US analyst coverage. No options market. OTCQX ADR structure.

Backing out market-implied probabilities from the enterprise value (estimated ~EUR 99M, based on ≈58M shares outstanding estimated from the April 2026 raise mechanics):

• Assign EUR 35M to ARC-EX at 5× forward product revenue
• Residual EUR 64M attributed to ARC-IM pipeline and optionality
• At a discounted NPV of EUR 312M for ARC-IM at full success: market implies ≈21% probability of ARC-IM commercial success

Analyst estimate: P(interim positive) × P(PMA | positive) × P(commercial success) = 55% × 75% × 80% = 33%. Gap: 12 percentage points, worth ≈$0.69/ADR at current implied values. (Sensitive to shares outstanding estimate; ±15% shares shifts this figure proportionally.)

The Q2 VA bolus (~EUR 600K unrecognized) adds another ≈$0.37/ADR of near-term mispricing. Combined identified edge: ≈$1.06/ADR vs $3.48 current, implying fair value near $4.50.

Cash per ADR: $1.45 (42% of current price). Realistic downside floor is ≈$2.00–2.20 after 12-18 months of continued burn.

Why the Gap Exists

Information friction, not fundamental disagreement. The VA dry-powder mechanism is buried in a call transcript no institutional buyer has read, on a stock structured as an OTCQX ADR with a Euronext primary listing. There are zero US sell-side models. The company has an explicit no-guidance policy, which further limits institutional modeling.

Sector rotation is mechanical. MedTech is at a historic low versus the S&P 500 (CEO's own words). The discount is applied uniformly to sector names regardless of company-specific catalysts. ONWRY's ARC-IM binary in early 2027 is discounted as if it were a sector ETF.

The counterparty hasn't synthesized the mechanism. Five other small medtech companies described the identical VA FSS → evaluation → PO cycle in their own Q1 2026 earnings calls: NRXS explicitly told investors not to expect Q1 VA revenue post-FSS; KMTS described being "handicapped spinning wheels" without FSS; ECOR built 71%+ of revenue through this same ramp to 15,000 VA patients; LUCD described center-by-center PO generation against individual federal budgets. The procurement pattern is validated across multiple independent sources, but the synthesis has not propagated to ONWRY holders.

Risks

1. Revenue-burn gap. EUR 1.3M Q1 product revenue against EUR 45M annual burn. This is not a near-term solvency issue (EUR 89.8M cash, two years of runway), but the path to self-sufficiency requires either ARC-IM approval or an acquisition. ARC-EX alone at current trajectory does not close the gap.

2. VA timing slippage. Management said "most convert Q2" but VA center budgets are individual, not system-wide. Some of the ≈23 evaluation units may slip to Q3 calendar. The mechanism is right; the one-quarter precision is management's assertion, not independently benchmarked at that duration.

3. OTCQX liquidity. Trades by appointment. The +9.25% single-day move on 0.2× average volume demonstrates how illiquid this name is — entry and exit both carry meaningful market impact risk at any position size that matters.

4. Empower BP binary. The 20% fails scenario (-50% stock impact at 0.45 loading) is the primary downside driver on a 12-month horizon. A sham-controlled pivotal for a first-in-class indication carries genuine uncertainty regardless of prior proof-of-concept data.

5. Nasdaq uplisting deferred. The Nasdaq uplisting process was prominently highlighted in Q4 2025 and is entirely absent from Q1 2026. Market conditions and stock price near the 52-week low are the stated reason. This removes a capital markets catalyst and limits the institutional buyer universe until resolved.

Catalysts

August 2026 — Q2 earnings. Primary resolution event for the VA conversion thesis. Product revenue ≥ EUR 1.7M confirms the bolus (P=0.58). Revenue < EUR 1.5M with softened VA language is the most immediate bearish trigger.

December 2026 — Year-end VA hub count. Target: all 25 VA hubs. Currently at ≈12-13 (≈50%). (P=0.45). Pace toward this target through H2 is the best leading indicator of the durable VA channel thesis.

Early 2027 — Empower BP interim analysis (33 patients at 3-month follow-up). Dominant long-term catalyst. Positive → major de-risk of H2 2028 PMA and expansion of implied ARC-IM value. (P=0.55).

What Would Change Our Mind

Bearish pivot:

• Q2 product revenue < EUR 1.5M and management downgrading VA conversion language from "very high" to qualified or silent
• Any 8-K or press release signaling Empower BP enrollment is materially below pace for early 2027 interim (requires ≈33 patients enrolled by ~Q3 2026)
• Annual burn rate increasing materially above EUR 45M, compressing runway below 18 months
• DOGE procurement action explicitly targeting VA medical device evaluation programs (not currently the case — disruption has been selective, hitting IT services and R&D more than clinical devices)

Thesis strengthening:

• Q2 confirms ≥75% VA conversion rate with management explicitly disclosing the number
• Any 8-K announcing an Ottobock commercial distribution agreement (Ottobock is #2 shareholder; Myomo's Q1 call confirmed Ottobock is actively building US SCI device infrastructure)
• Nasdaq uplisting process resumed — any SEC filing under Onward Medical NV indicating active registration

Evidence